{
  "id": "63eef8d6f36125a42600000f",
  "type": "factoid",
  "question": "L9LS was developed for which disease?",
  "ideal_answer": "L9LS was developed for malaria.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36260982",
    "http://www.ncbi.nlm.nih.gov/pubmed/35921449"
  ],
  "snippets": [
    {
      "text": "METHODS: We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria infection in healthy adults who had never had malaria or received a vaccine for malaria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection, without evident safety concerns.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.1 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36260982",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "malaria"
}